FY)BROX

FY)BROX

$40.80
PAN111

Fy)Brox is a potent anti-fibrotic formula. These ingredients work synergistically to inhibit fibrosis, notably by inhibiting the action of proinflammatory cytokines and TGF-β signalling.

 

                                           

Supplement Facts

Serving Size: 1 capsules

Servings Per Container: 60

    
 

Amount Per Serving

% Daily Value
Quercetin 40 mg †
Scutellaria Baicalensis (methanol extraction, contains Baicalein 85%) 30 mg †
Scutellaria Baicalensis (methanol extraction, contains Baicalin 85%) 30 mg †
Scutellaria Baicalensis (methanol extraction) 100 mg †
Rhuem Rhabarbarum  (contains Emodin 95%) 20 mg †
Rheum Palmatum (methanol extraction) 50 mg †
Salvia Miltiorrhiza (contains Salvianolic Acid B 5% 30 mg †
Salvia Miliorrhiza (methanol extraction) 100 mg †
Artemisia Annua (Contains Oridinin 0.5%) 30 mg †
Rabdosia Rubescens (contains Oridoin 0.5%) 20 mg †
Vaccinicum sect. Cyanoccus                   (contains Pterostilbene 98%) 30mg  †
Panax Ginseng (contains Ginsenoside Rg1 20%) 20 mg †
† Daily Value not established.

Other Ingredients: Vegetable cellulose (hypromellose); Vegetable Stearic Acid; Microcrystalline Cellulose and Vegetable Magnesium Stearate.

Does Not Contain: Wheat, gluten, soy, milk, eggs, fish, crustacean shellfish, tree nuts, peanuts

FY)BROX

DESCRIPTION

Fy)Brox is a potent anti-fibrotic formula. These ingredients work synergistically to inhibit fibrosis, notably by inhibiting the action of proinflammatory cytokines and TGF-β signalling.

PRODUCT INFORMATION

There is accumulating evidence suggestive of beneficial effects of plants used in traditional Chinese medicine and compounds isolated from medicinal plants in the treatment of fibrotic diseases. Methanol extracts of Scutellaria baicalensis, Salvia miltiorrhiza and Rheum palmatum, which are rich sources of baicalein, baicalin, salvianolic acid B and emodin, respectively, showed in vitro anti- fibrotic activities.

DOSAGE

 60 x 500mg vegetable capsules

1 to 2 capsules daily. 2 to 4 capsules daily in acute conditions.

TCM ACTIONS

INDICATIONS

ACTIONS

•       Clears ‘Heat’

•       Drains ‘Dampness’

•       Drains ‘Fire’ and ‘Detoxifies’

•       ‘Purges accumulations’

•       Regulate/Invigorate ‘Blood

•       Idiopathic pulmonary fibrosis

•       Cirrhosis

•       Progressive kidney disease

•       Cardiovascular fibrosis

•       Systemic sclerosis

•       Chemotherapy induced fibrosis

•       Inhibits fibrosis

 

CAUTIONS AND CONTRAINDICATIONS

May cause loose stools. Contraindicated with warfarin (coumadin). Use with caution in early stage cancers.

 

 

Fibrosis: Pathophysiology

  • Fibrotic tissue deposition is a normal wound-healing response. Dysregulation of this process leads to excessive extracellular matrix (ECM) accumulation (e.g., collagen, fibronectin), resulting in tissue stiffness and loss of architecture【1】.
  • Cytokines (IL-1, IL-6, TNF, TGF-β) promote IL-17-secreting cells. IL-17A has been identified as a key driver of fibrosis across multiple organs including lung, liver, kidney, heart, and skin【1】.
  • Triggers of fibrosis include chronic inflammation, physical/chemical/radiation injury, autoimmune dysfunction, and pathogens【2】.
  • Signalling pathways such as PI3K/Akt and TGF-β are potential targets for modulation【2】.

See Figure 1: Divergent cytokine pathways in fibrosis (adapted from Henderson, Rieder & Wynn 2020)【1】.

See Figure 2: Collagen linearisation and cross-linking in fibrosis (adapted from Cox & Erler 2014)【2】.

Fibrosis & Cancer

  • Inflammation → Fibrosis → Cancer: Chronic inflammation drives fibrosis, which predisposes tissues to oncogenic transformation【4】【5】.
  • Up to 20% of cancers are linked to chronic inflammation-associated fibrosis【5】.
  • Early ECM thickening may initially restrict tumour growth, but stromal reprogramming later supports tumour progression and metastasis【5】.
  • Chemotherapy-induced fibrosis: Drugs such as bleomycin, methotrexate, and gemcitabine may cause pulmonary fibrosis【5】.
  • Breast cancer has been associated with hepatic inflammation and fibrosis【6】.
  • Tumour-derived signals recruit fibroblasts and immune cells → stromal expansion (desmoplasia) and altered tumour microenvironment【7】.
  • TGF-β signalling contributes to excessive fibrillar collagen deposition and fibrosis【8】【9】.

Active Components – Mechanisms of Action

Quercetin

  • Modulates AKT activation in senescent pulmonary fibroblasts → alters cell survival pathways【10】.
  • Reported to reduce bleomycin-induced pulmonary fibrosis in preclinical models【10】.
  • Decreases collagen I protein expression【10】.

Baicalein

  • Inhibits TGF-β1/PDGF-induced fibroblast activation in systemic sclerosis models【11】.
  • Reduces IL-6 and TNF-α, thereby lowering hepatic stellate cell activation and ECM deposition【12】.

Baicalin

  • Mediates CaMKII and PI3K/AKT signalling to inhibit fibroblast proliferation【13】.
  • Reduces collagen deposition and hydroxyproline content via ERK1/2 and adenosine A2A receptor modulation【12】.
  • Inhibits NF-κB and inflammasome pathways【12】.
  • Reported to inhibit intestinal inflammation and fibrosis when combined with Boswellia serrata (Laudadio et al., 2024).

Salvianolic Acid B

  • Enhances antioxidant defence (HO-1, GSH-Px); inhibits NOX-2/4 and TLR4/NF-κB signalling → reduces oxidative stress and myofibroblast proliferation【14】.
  • Described as a multi-target agent in pulmonary and hepatic fibrosis【14】.
  • Salvia miltiorrhiza root has been specifically studied in myocardial fibrosis models (Li et al., 2025).

Emodin

  • Inhibits NF-κB nuclear translocation via reduced HMGB1/IKKγ expression → decreases fibrosis signalling【15】.
  • Regulates apoptosis and collagen synthesis in hepatic stellate cells【15】.
  • Comprehensively reviewed as an anti-fibrotic phytochemical in 2023 (HaoShang et al., 2023).

Artemisinin

  • Suppresses α-SMA and collagen IV expression via Notch pathway inhibition → reduces fibroblast activation【3】.
  • Inhibits VEGF/VEGFR2 signalling → decreases angiogenesis and tumour-related fibrosis【3】.
  • Reviewed in 2021 as a promising anti-fibrotic agent (Dolivo et al., 2021).

Oridonin

  • Inhibits NLRP3 inflammasome → reduces CCl₄-induced hepatic fibrosis【16】.
  • Enhances Nrf2-mediated antioxidant and anti-inflammatory effects【16】.
  • Suppresses α-SMA and COL1A1 expression in pulmonary fibroblast models【16】.
  • Preclinical work confirms antifibrotic activity in liver fibrosis (Liu et al., 2020).

References

  1. Henderson NC, Rieder F, Wynn TA. Fibrosis: from mechanisms to medicines. Nature. 2020;587(7835):555-66.
  2. Cox TR, Erler JT. Molecular Pathways: Connecting Fibrosis and Solid Tumor Metastasis. Clin Cancer Res. 2014;20(14):3637-43.
  3. Dolivo D, Weathers P, Dominko T. Artemisinin and artemisinin derivatives as anti-fibrotic therapeutics. Acta Pharm Sin B. 2021;11(2):322-39. https://doi.org/10.1016/j.apsb.2020.09.001
  4. López-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med. 2009;1(6-7):303-14.
  5. Chandler C, Liu T, Buckanovich R, Coffman LG. The double-edged sword of fibrosis in cancer. Transl Res. 2019;209:55-67.
  6. Sannappa Gowda NG, Shiragannavar VD, et al. Quercetin activates vitamin D receptor and ameliorates breast cancer induced hepatic inflammation and fibrosis. Front Nutr. 2023;10.
  7. Shekhar MP, Pauley R, Heppner G. Host microenvironment in breast cancer development: ECM-stromal contribution. Breast Cancer Res. 2003;5(3):130-5.
  8. Kaminski N, Allard JD, et al. Global analysis of gene expression in pulmonary fibrosis. PNAS. 2000;97(4):1778-83.
  9. Finkelstein JN, Johnston CJ, et al. Early ECM and TGF-β gene expression in mouse lung indicative of fibrosis. Int J Radiat Oncol Biol Phys. 1994;28(3):621-31.
  10. Hohmann MS, Habiel DM, et al. Quercetin reduces lung fibrosis in vivo. Am J Respir Cell Mol Biol. 2019;60(1):28-40.
  11. Peng B, Hu Q, He R, et al. Baicalein alleviates fibrosis and inflammation in systemic sclerosis. BMC Complement Med Ther. 2023;23.
  12. Hu Z, Guan Y, Hu W, et al. Overview of baicalin and baicalein pharmacology. Iran J Basic Med Sci. 2022;25(1):14-26.
  13. Zhao H, Li C, Li L, et al. Baicalin alleviates bleomycin-induced pulmonary fibrosis via PI3K/AKT. Mol Med Rep. 2020;21(6):2321-34.
  14. Xiao Z, Liu W, Mu Y-p, et al. Pharmacological effects of Salvianolic Acid B against oxidative damage. Front Pharmacol. 2020;11.
  15. HaoShang, Jia X, Liu H, Zhang X, Shao Y. A comprehensive review of emodin in fibrosis treatment. Fitoterapia. 2023;165:105358. https://doi.org/10.1016/j.fitote.2022.105358
  16. Li X, Zhang C-T, Ma W, Xie X, Huang Q. Oridonin: pharmacology, pharmacokinetics and toxicity. Front Pharmacol. 2021;12.
  17. Laudadio I, Leter B, Palone F, et al. Inhibition of intestinal inflammation and fibrosis by Scutellaria baicalensis and Boswellia serrata. Immun Inflamm Dis. 2024;12(10):e70036. https://doi.org/10.1002/iid3.70036
  18. Li Q, Ren C, Jiang B, et al. Salvia miltiorrhiza root in myocardial fibrosis. Front Pharmacol. 2025;16:1554696. https://doi.org/10.3389/fphar.2025.1554696
  19. Liu D, Qin H, Yang B, et al. Oridonin reduces liver fibrosis via NLRP3 inflammasome inhibition. Drug Dev Res. 2020;81(4):526-33. https://doi.org/10.1002/ddr.21649